A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)

Trial Profile

A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2018

At a glance

  • Drugs INXN 4001 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; First in man
  • Sponsors Xogenex
  • Most Recent Events

    • 21 May 2018 According to an Intrexon Corporation media release, the Precigen announced that the first patient has been dosed in this study.
    • 09 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 03 Apr 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top